HomeCompareMONTX vs ABBV

MONTX vs ABBV: Dividend Comparison 2026

MONTX yields 21.93% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $20.2K in total portfolio value· pulled ahead in Year 9
10 years
MONTX
MONTX
● Live price
21.93%
Share price
$28.70
Annual div
$6.29
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$82.1K
Annual income
$8,239.11
Full MONTX calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — MONTX vs ABBV

📍 ABBV pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMONTXABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MONTX + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MONTX pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MONTX
Annual income on $10K today (after 15% tax)
$1,864.10/yr
After 10yr DRIP, annual income (after tax)
$7,003.24/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $14,052.76/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MONTX + ABBV for your $10,000?

MONTX: 50%ABBV: 50%
100% ABBV50/50100% MONTX
Portfolio after 10yr
$92.2K
Annual income
$16,505.43/yr
Blended yield
17.89%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

MONTX
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MONTX buys
0
ABBV buys
0
No recent congressional trades found for MONTX or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMONTXABBV
Forward yield21.93%3.06%
Annual dividend / share$6.29$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$82.1K$102.3K
Annual income after 10y$8,239.11$24,771.77
Total dividends collected$48.9K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MONTX vs ABBV ($10,000, DRIP)

YearMONTX PortfolioMONTX Income/yrABBV PortfolioABBV Income/yrGap
1$12,893$2,193.06$11,550$430.00+$1.3KMONTX
2$16,438$2,642.55$13,472$627.96+$3.0KMONTX
3$20,738$3,148.73$15,906$926.08+$4.8KMONTX
4$25,902$3,712.42$19,071$1,382.55+$6.8KMONTX
5$32,048$4,333.53$23,302$2,095.81+$8.7KMONTX
6$39,303$5,011.13$29,150$3,237.93+$10.2KMONTX
7$47,797$5,743.43$37,536$5,121.41+$10.3KMONTX
8$57,671$6,527.82$50,079$8,338.38+$7.6KMONTX
9← crossover$69,069$7,361.02$69,753$14,065.80$684.00ABBV
10$82,143$8,239.11$102,337$24,771.77$20.2KABBV

MONTX vs ABBV: Complete Analysis 2026

MONTXStock

The fund invests at least 65% of its net assets in common stocks of companies of all market capitalization ranges, although the Adviser expects that the fund will primarily invest in common stocks of large-cap companies (those with market capitalizations of at least $10 billion measured at the time of investment). It may invest in more volatile sectors, which could result in a disproportionate return or loss compared to the S&P 500® Index. The fund may invest up to 5% of its net assets in ETFs and up to 10% of its net assets in foreign stocks, which is accomplished primarily through ADRs.

Full MONTX Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this MONTX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MONTX vs SCHDMONTX vs JEPIMONTX vs OMONTX vs KOMONTX vs MAINMONTX vs JNJMONTX vs MRKMONTX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.